Molecular pathology of melanoma

Cancer and Metastasis Reviews

Volumn 16, Issue 1-2, 1997, Pages 141-154

  Newton Bishop, Julia A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

immunotherapy; melanoma; p16; RT PCR; tumour antigens

Indexed keywords

CONTROLLED STUDY; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANTIGENS, NEOPLASM; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MELANOMA; PEDIGREE; PROGNOSIS; SKIN NEOPLASMS;

EID: 0030945848     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005752510012     Document Type: Review

References (114)

1. Balch CM, Soong S-J, Shaw HM: A comparison of worldwide melanoma data. In: Balch CM, Milton GW (eds) Cutaneous Melanoma. Lippincott, 507-518, 1985
2. MacLennan R, Green AC, McLeod GRC, Martin NG: Increasing incidence of cutaneous melanoma in Queensland, Australia. JNCI 84 (18): 1427-1432, 1992
3. MacNeill IB, Elwood JM, Miller D, Mao Y: Trends in mortality from melanoma in Canada and prediction of future rates. Stat Med 14: 821-839, 1995
4. Balch CM, Shaw HM, Soong S-J, Milton GW: Changing trends in the clinical and pathologic features of melanoma. In: Balch CM, Milton GW (eds) Cutaneous Melanoma. Lippincott, 313-319, 1985
5. Doherty VR, MacKie RM: Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ 297: 388-391, 1988
6. Stenn KS, Arons M, Hurwitz S: Patterns of congenital nevocellular nevi. A histologic study of thirty-eight cases. J Am Acad Dermatol 9 (3): 388-393, 1983
7. Mancianti M-L, Clark WH, Hayes FA, Herlyn M: Malignant melanoma stimulants arising in congenital melanocytic nevi do not show experimental evidence for a malignant phenotype. Am J Pathol 136 (4): 817-829, 1990
8. Barnhill R, Flotte T, Fleischli M, Perez-Atayde A: Cutaneous melanoma and atypical Spitz tumours in childhood. Cancer 76: 1833-1845, 1995
9. Spitz S: Melanomas of childhood. Am J Pathol 24: 591-609, 1947
10. Binder SW, Asnong C, Paul E, Cochran AJ: The histology and differential diagnosis of Spitz nevus. Sem Diag Pathol 10 (1): 36-46, 1993
11. Reed RJ: Minimal deviation melanoma. Am J Surg Pathol 14 (1): 53-68, 1990
12. Barnhill RL, Mihm MC: The histopathology of cutaneous malignant melanoma. Sem Diag Pathol 10 (1): 47-75, 1993
13. Clark WH Jr: Human cutaneous malignant melanoma as a model for cancer. Cancer Metas Rev 10: 83-88, 1991
14. Ackerman AB, Milde P: Naming acquired melanocytic nevi. Common and dysplastic, normal and atypical or Unna. Miescher, Spitz and Clark. Am J Dermatopathol 14 (5): 447-453, 1992
15. Newton Bishop JA: The atypical naevus: A clinician's view-point. Prog Pathol 179-189, 1996
16. MacKie RM: Clinical and histological evidence of an association between benign melanocytic naevi and malignant melanoma. Pigment Cell 9: 48-58, 1988
17. Elder DE, Clark WH, Elenitsas R, Guerry IV D, Halpern AC: The early and intermediate precursor lesions of tumor progression in the melanocytic system: Common acquired nevi and atypical (dysplastic) nevi. Sem Diag Pathol 10 (1): 18-35, 1993
18. Burton RC, Coates MS, Hersey P et al.: An analysis of a melanoma epidemic. Int J Cancer 55: 765-770, 1993
19. Hamilton SR: Molecular genetics of colorectal carcinoma. Cancer 70: 1216-1221, 1992
20. Soballe P, Herlyn M: Cellular pathways leading to melanoma differentiation: Therapeutic implications. Mel Res 4: 213-223, 1994
21. Herlyn M, Menrad A, Koprowski H: Structure, function, and clinical significance of human tumor antigens. JNC1 82 (24): 1883-1889, 1990
22. Herlyn M, Shih I-M: Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res 7: 81-88, 1994
23. Hellström KE, Hellström I: Possibilities for active immunotherapy of human cancer. Cancer Invest 10 (4): 285-293, 1992
24. Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J: Identification of the S-endo 1 endothelial associated antigen. Biochem Biophys Res Commun 218: 210-216, 1996
25. Cillo C, Cantile M, Mortarini R, Barba P, Parmiani G, Anichini A: Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. Int J Cancer 66: 692-697, 1996
26. Peck D, Isacke C: CD44 phosphorylation regulates melanoma cell and fibroblast migration on, but not attachment to, a hyaluron substratum. Curr Biol 6: 884-890, 1996
27. Goebeler M, Kaufmann D, Brocker E, Klein C: Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci 109: 1957-1964, 1996
28. Guo Y, Ma J, Wang J et al.: Inhibition of human melanoma growth and metastasis in vivo by anti-CD44 monoclonal antibody. Cancer Res 54: 1561-1565, 1994
29. Thomas M: Production and characterisation of novel human monoclonal antibodies against malignant melanoma. PhD Thesis 1995
30. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ: GD3. A prominent ganglioside of human melanoma. Detection and characterization by mouse monoclonal antibody. J Exp Med 155: 1133-1147, 1982
31. Urmacher C, Cordon-Cardo C, Houghton AN: Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. Am J Dermatopathol 11 (6): 577-581, 1989
32. Vedralova E, Borovansky J, Hach P: Ganglioside profiles of experimental melanoma and of their melanosomal fractions. Mel Res 5: 87-92, 1995
33. Dippold WG, Bernhard H, Dienes HP, zum Buschenfelde Meyer K-H: Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur J Cancer Clin Oncol 24 (Suppl 2): S65-S67, 1988
34. Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83; 8694-8698, 1986
35. Livingston PO, Adluri S, Helling F et al.: Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-key-hole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12 (14): 1275-1280, 1994
36. Livingston P, Wong G, Adluri S et al.: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12: 1036-1044, 1994
37. Marincola F, Shamamian P, Simonis T et al.: Locus-specific analysis of human leukocyte antigen class 1 expression in melanoma cell lines. Immunotherapy 16: 13-23, 1994
38. D'Alessandro G, Zardawi I, Grace J, McCarthy WH, Hersey PP Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: Relation to biology of melanoma. Pathology 19: 339-346, 1987
39. Houghton A: Cancer antigens: Immune recognition of self and altered self. J Exp Med 180: 1-4, 1994
40. Jaeger E, Bernhard H, Romero P et al.: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumour vaccines with melanoma-associated antigens. Int J Cancer 66: 162-169, 1996
41. Bergman R, Dromi R, Trau H, Cohen L, Lichtig C: The pattern of HMB-45 antibody staining in compound Spitz nevi. Am J Dermatol 17: 542-546, 1995
42. Marincola F, Hijazi Y, Fetsch P et al.: Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell-lines and in situ lesions. J Immunother 19: 192-205, 1996
43. Traversari C, van der Bruggen P, Luescher IF et al.: A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176: 1453-1457, 1992
44. Rogner U, Wilke K, Steck E, Korn B, Poustka A: The melanoma antigen gene (MAGE) is clustered in the chromosomal band Xq28. Genomics 29: 725-731, 1995
45. Brasseur F, Rimoldi D, Lienard D et al.: Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 63: 375-380, 1995
46. Mulcahy K, Rimoldi D, Brasseur F et al.: Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer 66: 738-742, 1996
47. Wolfel T, Hauer M, Schneider J et al.: A p16 INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281-1284, 1995
48. Stone C, Lynch E, Linden M, Kubus J, Zarbo R: Immunocytochemical evaluation of proliferating cell nuclear antigen Ki-67 (MIB-1) and p53 in predicting survival of primary and metastatic malignant melanomas. Appl Immunohistochem 41:25-33, 1996
49. Morales-Ducret C, van de Rijn M, Smoller B: Bcl-2 expression in melanocytic nevi. Arch Dermatol 131: 915-918, 1995
50. Kanitakis J, Montazeri A, Ghohestani R, Faure M, Claudy A: Bcl-2 oncoprotein expression in benign nevi and malignant melanomas of the skin. Eur J Dermatol 5: 501-507, 1995
51. Zhai S, Yaar M, Doyle S, Gilchrest B: Nerve growth factor resues pigment cells from ultraviolet-induced apoptosis by upregulating bcl-2 levels. Exp Cell Res 224: .335-343, 1996
52. Sparrow L, English D, Heenan P, Dawkins H, Taran J: Prognostic significance of p53 over-expression in thin melanomas. Mel Res 5: 387-392, 1995
53. Montano X, Shamsher M, Whitehead P, Dawson K, Newton J: Analysis of p53 in human cutaneous melanoma cell lines. Oneogene 9: 1455-1459, 1994
54. Platz A, Ringborg U, Grafstrom E, Hoog A, Lagerlof B: Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: Increased immunopositivity in hereditary melanoma. Mel Res 5: 101-106, 1995
55. Albino AP, Nanus DM, Mentle IR et al.: Analysis of ras oncogenes in malignant melanoma and precursor lesions: Correlation of point mutations with differentiation phenotype. Oncogene 4: 1363-1374, 1989
56. Peris K, Cerroni L, Chimenti S, Soyer H-P, Kerl H, Hofler H: Proto-oncogene expression in dermal naevi and melanomas. Arch Dermatol Res 283: 500-505, 1991
57. Grichnik J, Ali W, Burch J et al.: KIT expression reveals a population of precursur melanocytes in human skin. J Invest Dermatol 106: 967-971, 1996
58. Takahashi H, Saitoh K, Kishi H, Parsons P: Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-kit proto-oncogene product (c-kit) in melanocytic tumours. Virchows-Arch 427: 283-288, 1995
59. Luo D, Chen H, Searles G, Jimbow K: Coordniated mRNA expression of c-kit with tyrosinase and TRP-1 in melanin pigmentation of normal and malignant human melanocytes and transient activation of tyrosinase by kit/SCF-R. Mel Res 5: 303-309, 1995
60. Parry D, Peters G: Temperature sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol 16: 3844-3852, 1996
61. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 16: 859-867, 1996
62. Kamb A, Gruis N, Weaver-Feldhaus J et al.: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440, 1994
63. Cannon-Albright L: Assignment of a locus for familial melanoma MLM, to chromosome 9P13-22. Science 258: 1148-1152, 1992
64. MacGeoch C, Newton Bishop J, Bataille V et al.: Genetic heterogeneity in familial malignant melanoma. Hum Molec Genet 3: 2195-2200, 1994
65. Gruis N, Sandkuijl L, Van der Velden P, Bergman W, Frants R: CDKN2 explains part of the clinical phenotype in Dutch familial multiple-mole melanoma (FAMMMM) syndrome families. Mel Res 5: 169-177, 1995
66. Walker G, Hussussian C, Flores J et al.: Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Molec Genet 4: 1845-1852, 1995
67. Borg A, Johansson U, Johannsson O et al.: Novel germline p16 mutation in familial malignant melanoma in Southern Sweden. Cancer Res 56: 2497-2500 1996
68. Wick S, Dubay MM, Imanil I, Brizuela L: Biochemical and mutagenic analysis of the melanoma tumour suppressor gene product/p16. Oncogene 11 (11): 2013-2019, 1995
69. Lilischkis R, Sarcevic B, Kennedy C, Warlters A, Sutherland R: Cancer associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer 66: 249-254, 1996
70. Yang R, Serrano M, Slater J, Leung E, Koeffler H: Analysis of p16INK4a and its interaction with CDK4. Biochem Biophys Res Commun 218: 254-259, 1996
71. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA: Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 54: 489-496, 1994
72. Hussussian CJ, Struewing JP, Goldstein AM et al.: Germline p16 mutations in familial melanoma. Nature Genet 8: 15-21, 1995
73. Quelle D, Zindy F, Ashmun R, Sherr C: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000, 1995
74. Glendening J, Flores J, Walker G, Stone S, Albino A, Fountain J: Homozygous loss of thep15 INK4B gene (and not the p16INK4 gene) during tumour progression in a sporadic melanoma patient. Cancer Res 55: 5531-5535, 1995
75. Zuo L, Weger J, Yang O et al.: Germline mutations in the p161NK4a binding domain of CDK4 in familial melanoma. Nature Genet 12: 97-99, 1996
76. Newton JA: Familial melanoma. Clin Exp Dermatol 18: 5-11, 1993
77. Rodriguez-Sains RS: Ocular findings in patients with dysplastic nevus syndrome. Ophthalmology 93: 661-665, 1986
78. Rodriguez-Sains RS: Ocular findings in patients with dysplastic nevus syndrome. An update. Dermatol Clin 9 (4): 723-728, 1991
79. Huebner K, Ohta M, Lubinski J, Berd D, Maguire H: Detection of specific alterations in cancer cells. Sem Oncol 23: 22-30, 1996
80. Maelandsmo G, Florenes V. Hovig E et al.: Involvement of the pRb/p16/cdk4/cyclin pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 73: 909-916, 1996
81. Reed J, Loganzo FJ, Shea C et al.: Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocylic lesions correlates with invasive stage of tumor progression. Cancer Res 55: 2713-2718, 1995
82. Merlo A, Herman J, Mao L et al.: 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 7: 633-634, 1995
83. Costello J, Berger M, Huang H, Cavanee W: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56: 2405-2410, 1996
84. Rigel DS, Friedman RJ, Kopf AW, Silverman MK: Factors influencing survival in melanoma. Dermatol Clin 9 (4): 631-641, 1991
85. Balch CM, Soong S-J, Shaw HM, Milton GW: An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Balch CM, Milton GW (eds) Cutaneous Melanoma. Lippincott, 321-351, 1985
86. Newton Bishop J: Current immunotherapy for melanoma. Cancer Surv 26: 321-333, 1996
87. Hieken T, Farolan M, Ronan S, Shilkaitis A, Wild L, Dasgupta T: Beta-3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 63: 169-173, 1996
88. Ghazvini S, Kroll S, Char D, Frigillana H: Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine and mitotic index in uveal melanoma. Invest Ophthal Vis Sci 36: 2762-2767, 1995
89. Reddy V, Gattuso P, Aranha G, Carson H: Cell proliferation markers in predicting metastases in malignant melanoma, J Cut Pathol 22: 248-251, 1995
90. Sparrow LE, Soong R, Dawkins HJS, Iacopetta BJ, Heenan PJ: p53 gene mutation and expression in naevi and melanomas. Mel Res 5: 93-100, 1995
91. Abbott K, Harman G: Combination chemotherapy for disseminated malignant melanoma. Anti-Cancer Drugs 6: 489-497, 1995
92. Berd D, Mastrangelo M: Combination chemotherapy of metastatic melanoma. J Clin Oncol 13: 786-797, 1995
93. Bigner D, Brown M, Coleman R et al.: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 1311-radiolabelled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Mel-14F (ab′) 2 - a preliminary report. J Neurooncol 24: 109-122, 1995
94. Minasian L, Yao T, Steffens T et al.: A phase 1 study of anti-GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage colony stimulating factor in patients with metastatic melanoma. Cancer 75: 2251-2257, 1995
95. Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46: 3183-3191, 1986
96. Rosenberg S, Packard B, Aebersold P et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. New Engl J Med 319: 1676-1681, 1988
97. Rosenberg S, Lotze M, Muul L, Chang A, Avis F et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. New Engl J Med 316: 889-897, 1987
98. Spagnoli G, Schaefer C, Willimann T et al.: Peptide-specific CTL in tumor infiltrating lymphocytes from metastatic melanomas expressing MART-1/Melan-A, gp100 and tyrosinase genes: A study in an unselected group of HLA-A2.1 positive patients. Int J Cancer 64: 309-315, 1995
99. Salgaller M, Afshar A, Marincola F, Rivoltini L, Kawakami Y, Rosenberg S: Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res 55: 4972-4979, 1995
100. Hart I: Tissue specific promotors in targeting systemically delivered gene therapy. Sem Oncol 23: 154-158, 1996
101. Vile R: Tumour specific gene therapy. Cancer Biol 5: 429-436, 1994
102. Mittelman A, Wang X, Matsumoto K, Ferrone S: Antiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antidiiotypic monoclonal antibody MK2-23. Hybridoma 14: 175-181, 1995
103. Hersey P: Melanoma vaccines. Current status and future prospects. Drugs 47: 373-382, 1994
104. Morion D, Foshag L, Hoon D et al.: Prolongation of survival in metastatic melanoma alter active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216: 463-483, 1992
105. Bystryn J-C, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL: Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61: 1065-1070, 1988
106. Wölfel T, Hauer M, Klehmann E et al.: Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymophocytes (CTL). Int J Cancer 55: 237-244, 1993
107. Herman J, Bruggen PV, Luescher I et al.: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognise tumour cells expressing MAGE3. Immunogeneties 43: 377-383, 1996
108. Buzaid A, Tinoco L, Ross M, Legha S, Benjamin R: Role of computed tomography in the staging of patients with localregional metastases of melanoma. J Clin Oncol 13: 2104-2108, 1995
109. Saleh MN, Miller DM, Peterson L et al.: Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma. J Clin Oncol 6 (6): 1059-1065, 1988
110. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair G: Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338: 1227-1229, 1991
111. Pittman K, Burchill S, Smith B et al.: Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 7: 297-301, 1996
112. Mellado B, Colomer D, Castel T et al.: Detection of circulating neoplastic cells by reverse transcriptasc polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 14: 2091-2097, 1996
113. Buzaid A, Balch C: Polymerase chain reaction for detection of melanoma in peripheral blood: Too early to assess clinical value. JNCI 88: 569-570, 1996
114. Newton Bishop J, Bataille V, Pinney E, Bishop D: Family studies in melanoma: Identification of the atypical mole syndrome (AMS) phenotype. Mel Res 4: 199-206, 1994